This #PharmacoequityFriday I’m sharing new research from our team out this week in @jamanetworkopen.com.
In a study of 1.6 million adults, we found that folks w. #AFib had >$11 K ⬆️ in annual medical costs (including nearly $2K ⬆️ for 💊💊) vs. those w/o AFib.
📝: jamanetwork.com/journals/jam...
A success story for a physician with Alzheimer's which, in spite of the obstacles outlined, is a precursor for our enhanced ability to prevent the disease in the future
gift link
www.wsj.com/opinion/i-ca...
Thrilled to hear @uressien.bsky.social at @dukemedschool.bsky.social speaking on Pharmacoequity
16.01.2026 13:42 — 👍 1 🔁 1 💬 0 📌 0
Glad to have contributed to this study examining #Pharmacoequity of newer disease modifying therapies for patients with rheumatoid arthritis.
Take a look at our paper below!
📝: www.jrheum.org/content/52/1...
Pharmacoequity turned 4 years old last month!
Had a wonderful time in Ann Arbor last week as this year’s McKesson Equity Series Speaker @ the University of Michigan College of Pharmacy sharing on the past, present, and future of this growing field.
Let’s work together to achieve #Pharmacoequity! 💊
Had a wonderful time at the National Academy of Medicine (@nam.edu) Annual Meeting last week, kicking off Year 2 of the Emerging Leaders in Health and Medicine! ✨
Always great to connect with mentors, role models, and friends at this meeting and to celebrate the new inductees into the Academy.
Every Wednesday evening for years I’ve opened the @nejm.org weekly email to dozens of the latest clinical trials of exciting new therapies.
Yet, the future diffusion and equitable dissemination & implementation of these drugs is FAR less studied.
So many opportunities to advance #Pharmacoequity. 💊
👏🏾👏🏾👏🏾
20.10.2025 22:09 — 👍 1 🔁 0 💬 1 📌 0
Interestingly this 2021 survey showed that nearly 1/3 of US physicians reported lack of knowledge of 💊s for tobacco cessation as a reason for not prescribing therapies.
📝: www.sciencedirect.com/science/arti...
Love the idea of a series focused on tobacco cessation globally, esp the role of #Pharmacoequity. 💊
But not sure there is evidence to support that it’s “lagging knowledge” driving ⬇️ rates of treatment in low and middle income countries. 🤔
Hoping for more data ahead.
www.nejm.org/doi/full/10....
My patient recently lost his Medicaid insurance and couldn’t afford his meds.
Just calculated the cost of his 13 💊 which would be $2300/month. That’s around $27,500/year.
The FPL for a family of 4 is ~$32,000.
This is not sustainable for the health and lives of our patients!
#Pharmacoequity
Walked into a #RiteAid in CA yday that was EMPTY. Sad.
“The hundreds of stores that are set to close within the year will limit many Americans' access to 💊 resulting in "pharmacy deserts"—less-connected communities being left w/o nearby drugstores.
#Pharmacoequity
www.newsweek.com/rite-aid-cvs...
In this week’s newsletter, we’re celebrating the well-deserved recognition our faculty and trainees have earned for their impact across education, research, clinical care, and community engagement. Read about the latest honors and achievements here: uclahs.fyi/3GZDVQQ
28.07.2025 22:38 — 👍 1 🔁 1 💬 0 📌 0So great to see you this visit, friend! Thanks for the warm welcome! 😃
11.06.2025 22:36 — 👍 3 🔁 0 💬 0 📌 0
What an outstanding @cudeptofmedicine.bsky.social grand rounds presentation by the inspiring @uressien.bsky.social ! #pharmacoequity "Pursuing Pharmacoequity: The Case of Atrial Fibrillation"
11.06.2025 21:33 — 👍 10 🔁 2 💬 1 📌 0
Can’t believe it’s been since 2022! At least it was late in the year so almost 2023 😂.
And agreed, this project doesn’t happen without @dusetzinas.bsky.social being incredibly generous and supportive. Grateful for you, Stacie!
This image is a visual abstract for a paper titled ‘Racial and Ethnic Disparities in Receipt of ERBB2-Targeted Therapy for Breast Cancer, 2010-2020”. This was a Retrospective Cohort study using a SEER-Medicare Linked Dataset. The sample comprised 12,765 beneficiaries with ERBB2-positive breast cancer, and included those diagnosed from January 2010 to December 2020. The primary outcome of the study was receipt of ERBB2-targeted therapy in 12 months after diagnosis. The primary findings showed a) an increase in overall receipt of ERBB2-targeted therapies from 41.3% to 64.3% over time, and that b) Black & Hispanic patients had a lower likelihood of receipt than White patients in 2010-11, with no differences by 2018-19. The findings suggest a narrowing of racial and ethnic disparities in receipt of therapies over time among older Medicare beneficiaries with ERBB2-positive breast cancer. Future work is needed to understand the practices that resulted in the narrowing of disparities to develop implementation strategies and improve pharmacoequity in breast cancer care.
Sharing a short thread here on our recent publication from earlier this month. This project was an incredible team effort, and truly would not have been possible without every co-author on this all-⭐ team!
Go give it a read here if interested: jamanetwork.com/journals/jam...
A short 🧵:
(1/x)
‼️ New Simultaneous 📝 at #SGIM25.
In 2023, lecanemab became the 1st disease-modifying 💊 for Alzheimer’s disease.
Led by 🌟 Frank Zhou, we found that early uptake of lecanemab still appears to be marked by racial, ethnic & socioeconomic disparities.
jamanetwork.com/journals/jam...
#Pharmacoequity
Congrats to the amazing, Renu! ✨
15.05.2025 15:32 — 👍 6 🔁 1 💬 0 📌 0
Pharmacoequity matters. Appreciate this work! #AGS25 @uressien.bsky.social
09.05.2025 20:03 — 👍 2 🔁 1 💬 0 📌 0
This image is a visual abstract for a paper titled ‘Racial and Ethnic Disparities in Receipt of ERBB2-Targeted Therapy for Breast Cancer, 2010-2020”. This was a Retrospective Cohort study using a SEER-Medicare Linked Dataset. The sample comprised 12,765 beneficiaries with ERBB2-positive breast cancer, and included those diagnosed from January 2010 to December 2020. The primary outcome of the study was receipt of ERBB2-targeted therapy in 12 months after diagnosis. The primary findings showed a) an increase in overall receipt of ERBB2-targeted therapies from 41.3% to 64.3% over time, and that b) Black & Hispanic patients had a lower likelihood of receipt than White patients in 2010-11, with no differences by 2018-19. The findings suggest a narrowing of racial and ethnic disparities in receipt of therapies over time among older Medicare beneficiaries with ERBB2-positive breast cancer. Future work is needed to understand the practices that resulted in the narrowing of disparities to develop implementation strategies and improve pharmacoequity in breast cancer care.
📋‼️Honored to share this newly published article that I helped lead!
Cannot thank @uressien.bsky.social enough - he has served as a friend, mentor, and sponsor throughout! And the whole study team who this wouldn’t have happened without!🙏🏽
Will post a longer thread on the findings soon - stay tuned!
‼️ NEW Paper.
Led by @sudkrishnamurthy.bsky.social we found wide disparities in receipt of ERBB2-targeted 💊 for Medicare enrollees w. breast cancer, disparities that did narrow by 2019.
We need more research to identify strategies to improve cancer #Pharmacoequity.
jamanetwork.com/journals/jam...
Screenshot of the article, "Disparities in High-Risk Medication Use—Implications for Health Equity and Deprescribing Practices"
Our new editorial in JAMA Network Open:
Lower rates of high-risk med use in minoritized Medicare beneficiaries may reflect access barriers, not better care. Highlights urgent need for equity in deprescribing practices & alternatives to PIMs. With @uressien.bsky.social jamanetwork.com/journals/jam...
In people with diabetes, GLP-1 and SGLT2i drugs were associated with less Alzheimer's disease and related dementias
jamanetwork.com/journals/jam...
NEW Academic Achievement Unlocked: Fellow of the American College of Physicians! ✨😅
Grateful to Dr. Eileen Barrett for the nomination and to my Dad, the first and best internal medicine doctor I know. 🤎👨🏾⚕️
#FACP
cc @gradydoctor.bsky.social
“…11% of people said they could not afford medication and care within the past 3 months, the highest level in the four years the survey has been conducted.
Over 1/3 said if they were to need medical care, they would not be able to pay for it.”
#Pharmacoequity
www.nytimes.com/2025/04/02/h...
"In labs around the world, scientists are using A.I. to search among existing medicines for treatments that work for rare diseases." And saving some lives.
@davidfajgenbaum.bsky.social
gift link
www.nytimes.com/2025/03/20/w...
Sharing my new JAMANetworkOpen study, showing disparities in patient-clinician communication experiences of adults with/without serious illness: jamanetwork.com/journals/jam.... Compared to those without, adults with serious illness were more likely to feel afraid to ask questions, 1/
19.03.2025 16:46 — 👍 5 🔁 1 💬 1 📌 0
99% of new medicines developed by the pharmaceutical industry depend on NIH research jamanetwork.com/journals/jam...
10.03.2025 14:14 — 👍 884 🔁 439 💬 18 📌 25
Had the pleasure of being invited (virtually) to both the University of Iowa College of Medicine and College of Dentistry to serve as a Distinguished Lecturer. 🖤💛
We need more than just talk right now to bring us closer to justice in health, but hoping to help inspire the future.
